MoonLake Immunotherapeutics (MLTX) Cash from Operations (2021 - 2026)

MoonLake Immunotherapeutics' Cash from Operations history runs 6 years deep, the most recent figure standing at 66286000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 73.8% year-over-year to 66286000.0 in Q1 2026; TTM through Mar 2026 was 224153000.0, a 60.36% decrease from a year earlier, with the FY2025 full-year figure at 196007000.0, down 68.12% from the prior year.
• Cash from Operations eased to 66286000.0 in Q1 2026 per MLTX's latest filing, from 58794000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 9024427.0 in Q1 2023 and bottomed at 66286000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 20760383.0 (2022), against an average of 28091288.24.
• Biggest YoY gain for Cash from Operations was 67.03% in 2022; the steepest drop was 13060.13% in 2022.
• Year by year, Cash from Operations stood at 11595982.0 in 2022, then fell by 6.45% to 12344159.0 in 2023, then sank by 292.68% to 48473000.0 in 2024, then retreated by 21.29% to 58794000.0 in 2025, then declined by 12.74% to 66286000.0 in 2026.
• Per Business Quant, the three latest MLTX Cash from Operations figures stand at 66286000.0 (Q1 2026), 58794000.0 (Q4 2025), and 44543000.0 (Q3 2025).